Associate Professor, Oncology, Mayo Medical School

Oncology

Dr. Patrick A. Burch practices Oncology. He went to Medical College of Wisconsin. Medical College of Wisconsin is ranked 54 in research and 62 in primary care medicine He received 1 awards: "Fellow (FACP)". Doctor Patrick A. Burch, MD is also a published MD. He has 16 publication published. The most recent publication is: Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.

Publications

---

• Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.
• Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study.
• Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
• The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.
• Obesity adversely affects survival in pancreatic cancer patients.
• Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup...
• Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.
• A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
• Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.
• Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin...
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
• Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
• A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.

Schools

---

• Medical College of Wisconsin

• Med College Of Wisconsin

• Johns Hopkins Hospital

Doctors Specialties

---

• Medical Oncology
• Oncology

Accepted Insurances

---

• Choice Plus POS II
• Great West Healthcare-Cigna PPO
• MultiPlan PPO

Awards

---

• Fellow (FACP)

Education

---

• Johns Hopkins University
• Medical College of Wisconsin Affiliated Hospitals
• Medical College of Wisconsin

Hospital

---

• Mayo Clinic - Rochester, Minnesota

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Janell N. Shaw, MD This Doctor is OpenDoctor Recommended.
	Dr. Keith C. Bible, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Charles L. Loprinzi, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Gary A. Croghan, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Brian A. Costello, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Joseph Rubin, MD This Doctor is OpenDoctor Recommended.
	Dr. David T. Owens, MD This Doctor is OpenDoctor Recommended.
	Dr. Michaela S. Banck, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Ronald L. Richardson, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert B. Diasio, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Axel F. Grothey, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Andreas S. Beutler, MD This Doctor is OpenDoctor Recommended. This doctor has more publications

---

Doctor Directory | TOS | twitter | FB | Angel | blog